Adalvo announces the addition of Letermovir Tablets to its growing antiviral portfolio, further strengthening its position in niche, high-value therapeutic areas.
Letermovir is a complex antiviral therapy indicated for the prophylaxis of cytomegalovirus (CMV) reactivation and disease in adult CMV-seropositive recipients [R+] of an allogeneic haematopoietic stem cell transplant (HSCT) or in CMV-seronegative patients who have received a kidney transplant from a CMV-seropositive donor [D+/R-].
With global 2024 sales of approximately $798 million and a 3Y CAGR of 37% (IQVIA), Letermovir represents a rare and growing opportunity in a specialised market with limited competition. The product is characterised by its low-volume, high-price profile, limited API sourcing, and expensive, technically challenging development.
Adalvo’s Letermovir program is supported by a clearly defined regulatory and IP pathway, enabling Day-1 launch in all major markets, positioning the product for early competitive advantage in one of the world’s largest healthcare markets.
This addition reflects Adalvo’s strategy to build a portfolio of complex, partner-ready products with clear commercial differentiation, supported by deep technical expertise and strong regulatory execution.
To explore licensing or partnership opportunities for Letermovir Tablets or other products within Adalvo’s antiviral pipeline, contact the team today.